Operating Income (Loss) in USD of Oncotelic Therapeutics, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Oncotelic Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • Oncotelic Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$491K, a 85% increase year-over-year.
  • Oncotelic Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$689K, a 81% increase year-over-year.
  • Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$3.58M, a 46.2% increase from 2023.
  • Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$6.65M, a 31.6% increase from 2022.
  • Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$9.72M, a 6.53% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Oncotelic Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$689K -$491K +$2.79M +85% 01 Jul 2025 30 Sep 2025 10-Q 17 Nov 2025
Q2 2025 -$3.48M -$66K +$30.6K +31.7% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 -$3.51M -$101K +$66.1K +39.5% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$3.58M -$31.5K +$45K +58.9% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$3.62M -$3.28M -$3.3M -22760% 01 Jul 2024 30 Sep 2024 10-Q 17 Nov 2025
Q2 2024 -$326K -$96.6K +$6.23M +98.5% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 -$6.55M -$167K +$96.9K +36.7% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$6.65M -$76.5K +$4.45M +98.3% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$11.1M $14.5K +$610K 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$11.7M -$6.32M -$6.07M -2366% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$5.64M -$264K +$4.08M +93.9% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$9.72M -$4.53M -$3.01M -199% 01 Oct 2022 31 Dec 2022 10-K 12 Apr 2024
Q3 2022 -$6.71M -$595K +$1.21M +67.1% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$7.92M -$256K +$3.51M +93.2% 01 Apr 2022 30 Jun 2022 10-Q 18 Aug 2023
Q1 2022 -$11.4M -$4.34M -$2.31M -113% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023
Q4 2021 -$9.13M -$1.51M +$1.82M +54.6% 01 Oct 2021 31 Dec 2021 10-K/A 20 Apr 2023
Q3 2021 -$10.9M -$1.81M -$193K -11.9% 01 Jul 2021 30 Sep 2021 10-Q 18 Nov 2022
Q2 2021 -$10.8M -$3.76M -$3.78M -27298% 01 Apr 2021 30 Jun 2021 10-Q 22 Aug 2022
Q1 2021 -$6.97M -$2.04M +$611K +23.1% 01 Jan 2021 31 Mar 2021 10-Q 23 May 2022
Q4 2020 -$7.58M -$3.33M -$2.09M -168% 01 Oct 2020 31 Dec 2020 10-K 15 Apr 2022
Q3 2020 -$5.49M -$1.62M -$686K -73.7% 01 Jul 2020 30 Sep 2020 10-Q 22 Nov 2021
Q2 2020 -$4.81M $13.8K +$1.17M 01 Apr 2020 30 Jun 2020 10-Q 20 Aug 2021
Q1 2020 -$5.98M -$2.65M -$1.67M -171% 01 Jan 2020 31 Mar 2020 10-Q 24 May 2021
Q4 2019 -$4.31M -$1.24M -$1.69M -376% 01 Oct 2019 31 Dec 2019 10-K 15 Apr 2021
Q3 2019 -$2.62M -$931K -$717K -335% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 -$1.9M -$1.16M -$1.01M -657% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 -$894K -$976K -$181K -22.8% 01 Jan 2019 31 Mar 2019 10-Q 29 Jun 2020
Q4 2018 -$713K $450K +$2.89M 01 Oct 2018 31 Dec 2018 10-K 14 May 2020
Q3 2018 -$3.6M -$214K +$3.33M +94% 01 Jul 2018 30 Sep 2018 10-Q 19 Nov 2019
Q2 2018 -$6.92M -$153K +$3.74M +96.1% 01 Apr 2018 30 Jun 2018 10-Q 19 Aug 2019
Q1 2018 -$10.7M -$795K +$3.18M +80% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$13.8M -$2.44M +$1.04M +29.9% 01 Oct 2017 31 Dec 2017 10-K 10 Apr 2019
Q3 2017 -$14.9M -$3.54M -$278K -8.52% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$14.6M -$3.9M -$226K -6.16% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$14.4M -$3.97M -$618K -18.4% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$13.8M -$3.48M +$503K +12.6% 01 Oct 2016 31 Dec 2016 10-K 17 Apr 2018
Q3 2016 -$14.3M -$3.26M +$337K +9.36% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 -$14.6M -$3.67M -$342K -10.3% 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017
Q1 2016 -$14.3M -$3.35M -$575K -20.7% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 -$13.7M -$3.98M -$1.33M -50.4% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2017
Q3 2015 -$12.3M -$3.6M -$146K -4.23% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$12.2M -$3.33M +$596K +15.2% 01 Apr 2015 30 Jun 2015 10-Q 02 Aug 2016
Q1 2015 -$12.8M -$2.78M -$149K -5.67% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016
Q4 2014 -$12.7M -$2.65M -$548K -26.1% 01 Oct 2014 31 Dec 2014 10-K 25 Mar 2016
Q3 2014 -$12.1M -$3.45M -$806K -30.5% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015
Q2 2014 -$11.3M -$3.92M -$2.27M -137% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015
Q1 2014 -$9.03M -$2.63M -$747K -39.7% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015
Q4 2013 -$8.28M -$2.1M -$426K -25.5% 01 Oct 2013 31 Dec 2013 10-K 30 Mar 2015
Q3 2013 -$7.85M -$2.65M -$408K -18.2% 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014
Q2 2013 -$7.45M -$1.66M +$622K +27.3% 01 Apr 2013 30 Jun 2013 10-Q 08 Aug 2014
Q1 2013 -$8.07M -$1.88M +$4K +0.21% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014
Q4 2012 -$8.07M -$1.67M +$700K +29.5% 01 Oct 2012 31 Dec 2012 10-K 30 Mar 2015
Q3 2012 -$8.77M -$2.24M +$1.31M +37% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013
Q2 2012 -$10.1M -$2.28M +$623K +21.5% 01 Apr 2012 30 Jun 2012 10-Q/A 18 Oct 2013
Q1 2012 -$10.7M -$1.89M +$1.18M +38.6% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013
Q4 2011 -$11.9M -$2.37M 01 Oct 2011 31 Dec 2011 10-K 20 Mar 2014
Q3 2011 -$3.55M +$82K +2.26% 01 Jul 2011 30 Sep 2011 10-Q 09 Nov 2012
Q2 2011 -$2.9M +$2.13M +42.3% 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012
Q1 2011 -$3.07M 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012
Q3 2010 -$3.64M 01 Jul 2010 30 Sep 2010 10-Q 10 Nov 2011
Q2 2010 -$5.03M 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011

Oncotelic Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$3.58M +$3.07M +46.2% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$6.65M +$3.07M +31.6% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$9.72M -$596K -6.53% 01 Jan 2022 31 Dec 2022 10-K 12 Apr 2024
2021 -$9.13M -$1.54M -20.3% 01 Jan 2021 31 Dec 2021 10-K/A 20 Apr 2023
2020 -$7.58M -$3.27M -75.9% 01 Jan 2020 31 Dec 2020 10-K 15 Apr 2022
2019 -$4.31M -$3.6M -505% 01 Jan 2019 31 Dec 2019 10-K 15 Apr 2021
2018 -$713K +$13.1M +94.9% 01 Jan 2018 31 Dec 2018 10-K 14 May 2020
2017 -$13.8M -$83K -0.6% 01 Jan 2017 31 Dec 2017 10-K 10 Apr 2019
2016 -$13.8M -$77K -0.56% 01 Jan 2016 31 Dec 2016 10-K 17 Apr 2018
2015 -$13.7M -$1.03M -8.16% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2017
2014 -$12.7M -$4.37M -52.8% 01 Jan 2014 31 Dec 2014 10-K 25 Mar 2016
2013 -$8.28M -$208K -2.58% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2015
2012 -$8.07M +$3.82M +32.1% 01 Jan 2012 31 Dec 2012 10-K 30 Mar 2015
2011 -$11.9M +$6.62M +35.8% 01 Jan 2011 31 Dec 2011 10-K 20 Mar 2014
2010 -$18.5M 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.